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Intravenous pacemaker lead implantation for small children is not performed routinely. Here, we report
the case of a pediatric patient who underwent endocardial lead implantation and follow-up for 16 years.
The patient was a 4-year-old boy who underwent total correction of pulmonary atresia with ventricular
septal defect following several palliative operations. After the patient underwent total correction, atrial
ﬂutter was noted. Atrial ﬂutter was successfully terminated by overdrive pacing. However, atrial ﬂutter
occurred again immediately after overdrive pacing. To treat atrial ﬂutter caused by sick sinus syndrome, a
screw-in type lead was attached to the free wall of the right atrium and an excess loop was left to allow
for the patient's growth. During the 16-year follow-up, no adverse effects were observed except for a
gradual increase in pacing threshold. The selection of a small-sized endocardial lead and an appropriate
entry vein, with meticulous management of the leads, makes implantation of an endocardial lead for
small children easier and safer.
& 2013 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Cardiac pacing using a myocardial lead is performed in small
children to treat congenital complete atrioventricular block or
bradycardia after cardiac surgery. Intravenous pacemaker lead
implantation has advantages over a myocardial lead including
lower frequency of exit block and better pacing threshold. How-
ever, intravenous pacemaker lead implantation has not been
performed routinely in small children because this approach
requires the consideration of growth of the child, an appropriate
entry site to avoid venous obstruction, and careful selection of the
lead. Here, we report the case of an intravenous pacemaker lead
implantation in a 5-year-old patient who has been followed for 16
years after the procedure.2. Case report
A 5-year-old boy was admitted for treatment of atrial ﬂutter
after correction of pulmonary atresia with ventricular septal
defect. The patient had undergone total correction of cardiac
disease at 4 years and 2 months of age after previous bilateralt Rhythm Society. Published by Els
ar Surgery, Kinki University
ma, Osaka, 589-8511, Japan.
kamoto).unifocalization for major aortopulmonary collateral arteries,
Blalock–Taussig shunt creation, and Brock operation were per-
formed. Atrial ﬂutter occurred after total correction of cardiac
defects in the patient at the age of 5 years. Atrial ﬂutter was
successfully terminated by overdrive pacing, but occurred again
immediately. Recurrence of atrial ﬂutter after overdrive pacing was
considered to be caused by sick sinus syndrome. Use of a
myocardial lead was initially considered to treat the sick sinus
syndrome. However, it would have been difﬁcult to attach a
myocardial lead at the optimal location in the right atrium for
AAI pacing, due to previous thoracotomies and cardiac surgery. A
screw-in type pacemaker lead Medtronic 4568-53 cm (Medtronic
Inc. Minneapolis, MN, USA) was inserted from a cephalic vein by
cutdown and attached to the free wall of the right atrium. To allow
for growth, an excess loop was left in the right atrium (Fig. 1).
Medtronic THERA™ (Medtronic Inc.) was implanted under the
major pectoral muscle. The patient's body weight, height, and
surface area at the time of operation were 14.3 kg, 101 cm, and
0.63 m2, respectively. After 16 years, the patient's body weight,
height, and surface area were 47.2 kg, 169.0 cm, and 1.52 m2,
respectively. Because of body growth, the endocardial lead was
stretched, causing a gradual increase in the radius of the endo-
cardial loop. The round shape of the endocardial lead from the
superior vena cava (SVC) to the left subclavian vein changed to a
straight shape with the stretching. At the ﬁrst pacemaker implan-
tation, the voltage of the intrinsic P wave, pacing threshold, and
lead impedance were 1.4–2.0 mV, 1 V at 0.4 ms, and 441 Ω,evier B.V. All rights reserved.
Fig. 1. (A) Upper chest radiography image immediately after implantation. The atrial lead is attached to the anterior wall of the right atrium. At implantation, the patient's
body weight, height, and surface area were 14.3 kg, 101 cm, and 0.63 m2, respectively. (B) Radiography image 2 years after implantation. (C) Radiography image 5 years after
implantation. (D) Radiography image 16 years after implantation. At 16 years after implantation, the patient's body weight, height, and surface area were 47.2 kg, 169.0 cm,
and 1.52 m2, respectively. The original curled atrial lead was straightened following body growth.
Table 1
Pacemaker follow-up data.
Date Intrinsic P wave
(mV)
Pacing threshold Lead impedance
(ohm)
06.06.1995 1.4–2.0 1 V (0.4 ms) 441
02.07.2000 1.0–1.4 1.5 V (0.4 ms)/0.09 ms
(2.5 V)
486
05.14.2002 1.4–2.0 1.25 V (1.0 ms)/0.15 ms
(2.5 V)
490
05.18.2008 1.3–1.4 6.6 V (0.5 ms) 575
01.28.2012 0.6 7.0 V (0.5 ms) 562
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voltage of the intrinsic P wave decreased during the follow-up
period. At the last generator exchange, the voltage of the intrinsic
P wave, pacing threshold, and lead impedance were 0.6 mV, 7.0 V
at 0.5 ms, and 562 Ω, respectively (Table 1). At the last pacemaker
clinic, the pacing mode, voltage of intrinsic P wave, generator
output, and lead impedance were AAI, 1.3–1.4 mV, 7.5 V at 1.0 ms,
and 575 Ω, respectively. Venous occlusion at the implantation side
is one of the disadvantages of transvenous implantation in
children. Because we had not previously inserted a new lead from
the subclavian vein, we had not checked whether the patient's left
subclavian vein, brachiocephalic vein, or superior vena cava were
occluded using a venogram or venous echo. However, dilatation of
superﬁcial veins on the anterior chest as collateral circulations for
the occluded veins has not been observed. Moreover, the patient
has never experienced swelling or pain in the upper extremities
due to venous occlusions. During the follow-up period, no adverse
phenomena, such as exit block, sensing failure, or lead ﬂoating,
were observed except for a gradual increase in pacing threshold.
However, the cause of the increasing capture threshold seems to
be an inﬂammatory reaction at the electrode-myocardial interface.
Increasing pacing threshold is not a phenomenon exclusive to
small children, but is also observed in adult patients.3. Discussion
The advantages of intravenous pacemaker lead implantation
are: access to pacing sites that myocardial leads cannot be
attached to, such as the intra-arterial septum; lower frequency
of exit block [1]; better pacing threshold at the atrium and
ventricle; and better sensing capability of intrinsic P waves [2],
compared with myocardial leads. However, this approach for small
children requires the consideration of growth, an appropriateentry site to avoid venous obstruction, and selection of a lead that
is unlikely to detach during growth. Furman and Young [3]
reported using an excess loop of endocardial lead to allow for
patient growth. Gheissari et al. [4] reported that an excess loop of
10 mm per year was needed to allow for patient growth. Because it
seems unlikely that 2 endocardial leads can be inserted into the
vein without venous occlusion, many authors consider that atrio-
venticular synchronous pacing for small children is not useful in
the treatment of atrioventicular block. Thus, in almost all reports
on transvenous pacemaker lead implantations, the authors
describe single chamber pacemaker implantation for VVI pacing.
To perform atrial pacing as in our patient, the estimated length of
excess loop left in the right atrium to allow for patient growth
must not exceed the length for right ventricular apical pacing.
Thus, the length of excess loop that should be left in the right
atrium is as long as the length for right ventricular pacing.
However, all of the excess loop estimated for right ventricular
pacing cannot always be left in the right atrium. To resolve this
problem, Strojanov et al. [5] suggested that the part of the lead
that could not be left in the right atrium can be left in the
pacemaker pocket, and that the lead should be ﬁxed to the
Table 2
Summary of papers on intravenous pacemaker lead implantation for small children.
Authors Entry vein Mode Age BH
(cm)
BW
(kg)Method
Furman and Young
[3]
1 month
Holmes et al. [6]
Subclavian
vein
18
months
75 8.6
Puncture
Gillette et al. [2]
Subclavian
vein
DDD/
VVI
o4 years o15
Puncture
Till et al. [7]
VVI Newborn 2.8
DDD 3 years 12.8
Guerola et al. [8]
Subclavian
vein DDD Newborn 1.2
Puncture
Sachweh et al. [9]
Cephalic vein
1.3 years 8.5
Cutdown
Strojanov et al. [10]
Cephalic vein
2.45
Cutdown
Kammraad et al. [11]
Subclavian
vein VVI 2 days 2.3
Puncture
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expectation of spontaneous lead migration as the child grows.
In this case, the excess loop in the atrium initially stretched and
the round shape of the endocardial lead from the SVC to the left
subclavian vein changed to a straight shape following growth. The
adhesion of the endocardial lead to the junction between the SVC and
the innominate vein has often been observed when endocardial
extractions are performed. Thus, tension on the endocardial lead will
not be passed directly to the excess loop in the right atrium and the
course of the lead will change from round to straight.
In 1977, Furman and Young [3] were the ﬁrst to report on
transvenous pacemaker lead implantation in 12 children and
adolescents. The youngest patient was 1 month old. After their
report, several other papers on endocardial pacemaker implanta-
tion in small children were published (Table 2) [2,3,6–11]. Gillette
et al. [2] reported transvenous pacing from the subclavian vein via
puncture. The criteria for transvenous pacemaker lead implanta-
tion were that the patient should be 44 years of age with a body
weight 415 kg. Till et al. [7] reported that smaller pacemaker
generator and transvenous lead established transvenous ventri-
cular pacing (VVI) in a newborn infant of 2.8 kg and atrioventri-
cular synchronized pacing (DDD) in children at the age of 3 years
and 12.8 kg body weight. Guerola et al. [8] reported 7 cases of
children who underwent dual-chamber pacemaker lead implanta-
tion with unipolar leads via subclavian vein puncture. The body
weight at operation was o4 kg and minimum body weight was
1.2 kg. There was a subclavian vein thrombosis in a 1.2 kg neonate
and nearly all the patients required lead advancement prior to
generator end-of-life. Sachweh et al. [9] and Strojanov et al. [10]
reported transvenous pacemaker lead implantation via the cepha-
lic vein by cutdown. Sachweh et al. [9] recommended that the
transvenous lead should be inserted via puncture of the subclavian
vein if the cephalic vein was too small in diameter or forward
movement of the lead was impossible. Kammeraad et al. [11]
reported endocardial lead implantation via subclavian vein punc-
ture in infants who weighed o10 kg (the minimum body weight
was 2.3 kg).
Molina et al. [12] reported that the entry vein should be
carefully selected according to patient age and that the size of
the entry vein should also be checked using vascular echo due to
variations in size. Furthermore, they reported that vein obstruction
frequently occurs for large endocardial leads occupying more thanhalf of the cross-sectional area of the entry vein. The entry vein
should thus have a cross-sectional area of more than twice the
sum of the cross-sectional areas of 2 leads if 2 leads for DDD
pacing are chosen. Bar-Cohen et al. [13] recently assessed the rate
of venous obstruction after pacemaker implantation for small
children using a venogram and concluded that age, size, and lead
factors alone do not predict venous obstruction. New leads could
be placed by advancing a wire past the obstruction, thus bypassing
the obstruction, or by advancing the new leads through tracts
created by extracted leads. However, the presence of venous
occlusion increases the procedural complexity in many of the
cases. Therefore, we have to choose a larger vein and to select a
smaller lead to decrease venous obstruction. We opted for a screw-
type lead to prevent lead detachment, as Williams et al. [14]
reported a case in which a tined lead became free-ﬂoating in the
late phase. Advancements in technology facilitate the use of
smaller diameter endocardial leads. According to the 2012–2013
Data Book Pacemaker & ICD/CRT [15], the diameter of FINELINE™ II
Storox (Boston Scientiﬁc, Natick, MA, USA) and Tendril™ (St. Jude
Medical Inc., St. Paul, MN, USA) is less than 2 mm. Unfortunately,
we have no experience of using Tendril for small children. FINE-
LINE is a 1.7 mm, bipolar, screw-in pacing lead. This lead can be
inserted into the vein using a 5 Fr sheath or directly by cutdown.
This lead does not have a retractable screw-in system. A small
amount of sugar covers the ﬁxed helix for the ﬁrst 5 min in the
bloodstream. Thus, this lead must be attached to the right atrium
or right ventricle before the sugar dissolves to prevent entangle-
ment with the tricuspid valve apparatus. The body of the lead also
has to be rotated to ﬁx it to the myocardium, which is not very
difﬁcult; however, it is occasionally difﬁcult to detach the lead
from the myocardium to identify a better pacing and sensing site.
Recently, the SelectSecure™ model 3839 lead (Medtronic Inc.) has
become commercially available in Japan. The SelectSecure is a
4.1 Fr, steroid-eluting, bipolar, ﬁxed-screw lumenless pacing lead.
Its small size makes it beneﬁcial for use in children. However, the
delivery system, an 8.4 Fr steerable catheter requiring a 9 Fr
introducer sheath, is not optimal for use in small children due to
its size and its large radius of curvature. Lapage and Rhee [16]
developed a 5 Fr checkFlo Performer™ Introducer set (Cook
Medical Inc., Bloomington, IN, USA) to optimize delivery without
the need for a large diameter introducer/sheath system. If we can
use this delivery system, SelectSecure is then an attractive lead to
use: the small outer diameter lead may prevent venous occlusion,
the steroid-eluting lead may prevent increasing pacing threshold
over time, and the lumenless lead may prevent lead fracture over
time. During the 16-year follow-up period in our patient, no
adverse phenomena, such as exit block, sensing failure, or free-
ﬂoating of the lead, were observed, except for a gradual increase in
pacing threshold. Intravenous pacemaker lead implantation has
many advantages compared with a myocardial lead. It is important
to avoid venous obstruction in the long term for good results after
pacemaker lead implantation, especially in small children. A small-
sized lead and an appropriate entry vein should be selected to
avoid venous obstruction after lead implantation.4. Conclusion
Implantation of an endocardial lead may be indicated for small
children, particularly for the treatment of atrial arrhythmia or
arrhythmia after cardiac surgery, if a small endocardial lead and an
appropriate entry vein can be selected.
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